..und eine emense Zeit und Kostenersparniss ( wenn es erstmal anläuft )
"Currently, the new facility is undergoing CQV (commissioning, qualification, and validation) in preparation for cGMP manufacturing to begin in the fourth quarter of 2019. It is a multi-product facility designed to produce three different drug substances: allogeneic CAR T cells, messenger RNA (including formulations development) and adeno-associated viral vectors. Precision intends to initially use this new manufacturing center to create clinical trial material for its Phase I/II clinical trials in 2020. Precision BioSciences? MCAT facility is designed to meet regulatory requirements in the United States, Europe and Japan."
Bin noch nicht eingestiegen. Schaue mir das noch an. Habe momentan andere Biotechs im Portfolio und will es mit diesen sehr spekulativen Aktien auch nicht übertreiben. Zumal dies hier alles noch in einer wirklich sehr frühen Phase ist.
Ich habe zwar auch CRISPR, Editas und Intellia, finde den Bereich NASH momentan aber spannender. Besonders, da es bei ein paar Unternehmen nun stark in Richtung potenzielle Zulassung geht.
"6 Wall Street analysts have issued ratings and price targets for Precision BioSciences in the last 12 months. Their average twelve-month price target is $22.80, suggesting that the stock has a possible upside of 153.33%. The high price target for DTIL is $24.00 and the low price target for DTIL is $21.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy.""
"...announced today that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019."
und gleich darauf :
Barclays Gene Editing & Gene Therapy Summit Nov 13, 2019 at 2:45 PM EST to Nov 13, 2019 at 12:00 AM EST Add to Outlook Add to Google Calendar Location New York, NY Speaker: Matt Kane, Chief Executive Officer
"Mr. Buehler has over thirty years of experience in the healthcare industry. He spent the majority of his career with Alcon Laboratories, a publicly traded ophthalmology-focused healthcare company headquartered in Fort Worth, Texas. At Alcon, Mr. Buehler rose through the commercial organization, eventually becoming CEO, leading the company?s sale to Novartis and subsequently serving as Alcon division head within Novartis. He will assume the chairmanship of Precision?s Nominating and Corporate Governance Committee (replacing Mr. Kane), and will also join the company?s Audit Committee (replacing Dr. Adelman)."